{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:38:46Z","timestamp":1792201126324,"version":"4.4.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1097\/md.0000000000002176","type":"journal-article","created":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T05:34:56Z","timestamp":1449812096000},"page":"e2176","source":"Crossref","is-referenced-by-count":32,"title":["Low-Dose Versus Standard Dose of Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Bladder Cancer"],"prefix":"10.1097","volume":"94","author":[{"given":"Shuxiong","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhensheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20210309","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"R2-25-20210309","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"R3-25-20210309","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"R4-25-20210309","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bju.12012","article-title":"Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS)","volume":"112","author":"Witjes","year":"2013","journal-title":"BJU Int"},{"key":"R5-25-20210309","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"R6-25-20210309","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81\u200amg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27\u200amg in superficial bladder cancer","volume":"89","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2002","journal-title":"BJU Int"},{"key":"R7-25-20210309","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol"},{"key":"R10-25-20210309","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"R11-25-20210309","first-page":"152","article-title":"Low dose vs standard dose BCG therapy of superficial bladder cancer: final results of a phase 3 randomized trial","volume":"35","author":"Bassi","year":"1999","journal-title":"Eur Urol"},{"key":"R12-25-20210309","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1016\/j.juro.2014.02.1587","article-title":"Long term results of a double-blind randomized controlled trial of interferon alpha-2b and low dose bcg in patients with high risk non-muscleinvasive bladder cancer","volume":"191","author":"Esuvaranathan","year":"2014","journal-title":"J Urol"},{"key":"R13-25-20210309","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.0919-8172.2003.00607.x","article-title":"Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guerin for superficial bladder cancer recurrence","volume":"10","author":"Irie","year":"2003","journal-title":"Int J Urol"},{"key":"R14-25-20210309","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-5347(17)37532-8","article-title":"Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer","volume":"147","author":"Morales","year":"1992","journal-title":"J Urol"},{"key":"R15-25-20210309","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF02550276","article-title":"Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer","volume":"30","author":"Yalcinkaya","year":"1998","journal-title":"Int Urol Nephrol"},{"key":"R16-25-20210309","first-page":"S46","article-title":"A randomized control study to evaluate the efficacy, safety and QOL in low-dose bacillus calmette-guerin instillation therapy for non-muscle invasive bladder cancer","volume":"84","author":"Yokomizo","year":"2014","journal-title":"Urology"},{"key":"R17-25-20210309","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"R18-25-20210309","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/sim.3013","article-title":"Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category","volume":"27","author":"Hamling","year":"2008","journal-title":"Stat Med"},{"key":"R19-25-20210309","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R20-25-20210309","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R21-25-20210309","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.urology.2007.07.017","article-title":"The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma","volume":"70","author":"Agrawal","year":"2007","journal-title":"Urology"},{"key":"R22-25-20210309","first-page":"317","article-title":"A randomized trial comparing low dose (40 or 80\u200amg) with standard dose (120\u200amg) of bacillus calmette-guerin for superficial bladder cancer","volume":"4","author":"Vijjan","year":"2006","journal-title":"Indian J Urol"},{"key":"R23-25-20210309","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/0974-7796.106873","article-title":"Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guerin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison","volume":"5","author":"Inamoto","year":"2013","journal-title":"Urol Ann"},{"key":"R24-25-20210309","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.juro.2013.11.005","article-title":"5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guerin with epirubicin and interferon-alpha2b in patients with T1 bladder cancer","volume":"191","author":"Hemdan","year":"2014","journal-title":"J Urol"},{"key":"R25-25-20210309","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0022-5347(01)64936-X","article-title":"Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911","volume":"157","author":"Vegt","year":"1997","journal-title":"J Urol"},{"key":"R26-25-20210309","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"R27-25-20210309","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.purol.2012.12.010","article-title":"Bacillus Calmette-Guerin maintenance treatment in non-invasive bladder tumors: 1 year follow-up results of multicenter URO-BCG-4 trial. [French]","volume":"5","author":"Galliot","year":"2013","journal-title":"Prog Urol"},{"key":"R28-25-20210309","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/iju.12609","article-title":"Efficacy and tolerance of one-third full dose bacillus Calmette-Guerin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study","volume":"22","author":"Pfister","year":"2015","journal-title":"Int J Urol"},{"key":"R29-25-20210309","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5\u200amg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"R30-25-20210309","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2011.10.033","article-title":"Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations","volume":"61","author":"Mitropoulos","year":"2012","journal-title":"Eur Urol"},{"key":"R31-25-20210309","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S1569-9056(09)60277-3","article-title":"Can in vitro tumour cell culture and cyto immuno assay individualise intra vesical therapy for TCC of urinary bladder \u2013 an innovative idea","volume":"8","author":"Mohanty","year":"2009","journal-title":"Eur Urol, Suppl"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000002176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:55:26Z","timestamp":1620960926000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201512080-00025"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":29,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000002176","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}